How pharma companies can tackle drug resistance threats

The pharmaceutical industry is facing criticism for not taking the necessary steps to provide access to antibiotics and antifungals in low- and middle-income countries to combat the threat of antimicrobial resistance. A report by Access to Medicine Foundation has highlighted the importance of improving access to essential medicines to address the rising issue of drug resistance. Jayasere Iyer, CEO of Access to Medicine Foundation, discussed the findings of the report in an interview with CNBC Africa. He emphasized that drug resistance is a current problem affecting people around the world, with individuals in Africa facing some of the highest risks from drug-resistant infections due to a lack of access to treatment. The report evaluated 17 major pharmaceutical companies and their efforts to enable access to essential antibiotics and combat drug resistance in low-income countries. While progress has been made in research and development for new drugs and vaccines, millions of people still lack access to critical medicines. Iyer pointed out that Africa accounts for a significant portion of the global population but produces only a small percentage of medicines and vaccines, leading to a shortage of essential drugs in the region. He highlighted initiatives where pharmaceutical companies are transferring manufacturing knowledge to African countries and registering products for sale to improve access to medicines. Despite some positive steps taken by companies, more efforts are needed to ensure that patients receive the right treatment at the right time. The report also emphasized the importance of technology transfer in boosting the local supply of medicines. African countries heavily rely on drug imports from countries like India and China, resulting in limited access to essential drugs. By transferring manufacturing know-how to local producers in Africa, pharmaceutical companies can enhance the availability of antibiotics and antifungals for patients in low-income countries. Several companies have already initiated technology transfer projects in African countries, contributing to a more stable supply of essential medicines. Iyer expressed optimism about the progress made by some pharmaceutical companies in research and development efforts, particularly in the development of antibiotics and vaccines. While the antibiotic pipeline has seen an increase in projects, there is a need for more products to combat the rising threat of drug resistance. He highlighted the importance of ensuring equitable access to drugs and vaccines, especially in regions like sub-Saharan Africa that bear a high burden of disease and resistance. Companies are urged to work with partners to improve access through registration, supply chain enhancements, and technology transfer agreements. While there have been improvements in access planning over the years, significant gaps remain in addressing the global issue of antimicrobial resistance. More proactive measures and collaborative efforts are essential to tackle the challenges posed by drug resistance and ensure access to life-saving medicines for all individuals in need.